Edition:
United States

Galena Biopharma Inc (GALE.OQ)

GALE.OQ on NASDAQ Stock Exchange Capital Market

0.35USD
11:16am EDT
Change (% chg)

$-0.00 (-1.15%)
Prev Close
$0.35
Open
$0.35
Day's High
$0.35
Day's Low
$0.35
Volume
17,258
Avg. Vol
103,049
52-wk High
$8.16
52-wk Low
$0.27

Chart for

About

Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S),... (more)

Overall

Beta: 1.82
Market Cap(Mil.): $13.63
Shares Outstanding(Mil.): 38.41
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.87 16.18
EPS (TTM): -- -- --
ROI: -- 15.15 14.60
ROE: -- 16.38 13.87

BRIEF-Galena Biopharma, unit of co and Biovascular, enters amendment of exclusive license agreement

* Galena Biopharma-‍on Sept 5, unit of co and Biovascular, entered amendment of exclusive license agreement between MPI and BVI dated December 20, 2013

Sep 11 2017

BRIEF-Galena Biopharma and Biovascular Inc reaffirm GALE-401 partnership

* Galena Biopharma and Biovascular Inc reaffirm GALE-401 partnership

Sep 11 2017

Galena settles U.S. kickback charges related to opioid drug

Galena Biopharma Inc will pay more than $7.55 million to resolve charges it paid kickbacks to doctors to induce them to prescribe its opioid-based pain medication Abstral to patients, the U.S. Department of Justice said on Friday.

Sep 08 2017

UPDATE 1-Galena settles U.S. kickback charges related to opioid drug

Sept 8 Galena Biopharma Inc will pay more than $7.55 million to resolve charges it paid kickbacks to doctors to induce them to prescribe its opioid-based pain medication Abstral to patients, the U.S. Department of Justice said on Friday.

Sep 08 2017

BRIEF-U.S. DOJ says Galena Biopharma to pay over $7.55 mln to resolve alleged claims

* Department of Justice says "Galena Biopharma Inc to pay more than $7.55 million to resolve alleged false claims related to opioid drug"

Sep 08 2017

BRIEF-RXi Pharma announces completion of enrollment of phase 2 clinical trial

* RXi Pharmaceuticals announces completion of enrollment of phase 2 clinical trial with samcyprone for cutaneous warts Source text for Eikon: Further company coverage:

Sep 06 2017

BRIEF-Galena Biopharma reports Q2 loss per share $0.22

* Galena Biopharma reports second quarter 2017 financial results

Aug 14 2017

BRIEF-RXi Pharmaceuticals Corp reports Q2 loss per share $0.11‍​

* RXi Pharmaceuticals reports second quarter 2017 financial results and recent corporate highlights

Aug 10 2017

BRIEF-Galena Biopharma files for non-timely 10-Q- SEC Filing‍​

* Galena Biopharma - cannot complete by Aug 9, additional changes to June 30, 2017 form 10-q to include all necessary disclosure resulting from merger

Aug 09 2017

BRIEF-RXi Pharmaceuticals enters into common stock purchase agreement for up to $15.0 million

* RXi Pharmaceuticals enters into common stock purchase agreement for up to $15.0 million

Aug 09 2017

Competitors

Earnings vs. Estimates